<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): December 12, 1997
-------------------
LXR BIOTECHNOLOGY, INC.
- --------------------------------------------------------------------------------
(Exact name of Registrant as specified in its charter)
DELAWARE 1-12968 68-0282856
- --------------------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
1401 MARINA WAY SOUTH, RICHMOND, CALIFORNIA 94804
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code: (510) 412-9100
----------------
Not Applicable
- --------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE> 2
INFORMATION TO BE INCLUDED IN THE REPORT
ITEM 5. OTHER EVENTS
On December 12, 1997, LXR Biotechnology, Inc. ("LXR" or the "Company")
closed a private placement of 3,428,572 shares of its common stock (the
"Shares") at $1.75 per share, resulting in gross proceeds of approximately $6
million. The net proceeds, expected to be approximately $5.5 million, are to be
used by LXR for research and development and for general working capital.
The Shares were offered and sold without registration under the
Securities Act of 1933, as amended (the "Securities Act"), in reliance upon the
exemptions provided by Section 4(2) of the Securities Act and/or Rule 506 of
Regulation D promulgated by the Securities and Exchange Commission (the
"Commission") thereunder. The Shares were also offered and sold in reliance upon
exemptions from registration or qualification under certain state securities
laws. The Company has agreed to file a registration statement to cover resales
by the purchaser of the Shares.
2
<PAGE> 3
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits
10.1 Subscription Agreement dated December 12, 1997 between the
Company and Grace Brothers Limited
99.1 Press Release Issued by the Company on December 12, 1996
3
<PAGE> 4
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
LXR BIOTECHNOLOGY INC.
Date: December 15, 1997 By: /s/ L. David Tomei
-----------------------------------------
L. David Tomei, Chief Executive Officer
4
<PAGE> 5
EXHIBIT INDEX
Exhibit
- -------
10.1 Subscription Agreement dated December 12, 1997 between The Company
and Grace Brothers Limited
99.1 Press Release Issued by the Company on December 12, 1996
5
<PAGE> 1
Exhibit 10.1
SUBSCRIPTION AGREEMENT
LXR Biotechnology, Inc.
1401 Marina Way South
Richmond, CA 94804
Attn: Chief Executive Officer
Gentlemen:
1. Subscription. Pursuant to this Subscription Agreement (the "Agreement"),
Grace Brothers, Ltd. (the "Investor") is hereby purchasing from LXR
Biotechnology, Inc., a Delaware corporation (the "Company"), 3,428,572 shares
(the "Shares") of common stock, par value $0.0001 per share (the "Common
Stock"), of the Company for a purchase price of $1.75 per Share and an aggregate
purchase price of $6,000,0001 (the "Purchase Price").
2. Closing.
(a) On the date hereof (the "Closing") payment of the Purchase Price
is being made by electronic wire transfer in accordance with the following
instructions:
Bank Name Wells Fargo Bank
Bank Address: San Francisco
ABA#: 121000248
WFB Account #: 4068-000769
For further credit to Acct #358-138201
LXR Biotechnology Inc.
Attn: Laurie Vaugn
(650) 396-7189
or by delivery of a bank check or certified check made payable to LXR
Biotechnology, Inc., against delivery to the Investor of a certificate
representing the Shares.
(b) At the Closing, the Company shall deliver to the Investor the
following:
(i) a copy of the Charter Documents (as defined in Section
4(b)) and resolutions of the Board of Directors of the Company
authorizing and
<PAGE> 2
approving the issuance of the Shares and the execution, delivery
and performance of this Agreement, all such resolutions to be
certified by the Secretary of the Company;
(ii) a Certificate of Incumbency, dated as of the Closing
and executed by the Secretary of the Company certifying the
names, titles and signatures of the officers authorized to
execute this Agreement and the Shares;
(iii) certificates evidencing that the Company is in good
standing from the Secretary of State of the States of Delaware
and California;
(iv) a legal opinion of Company's counsel, dated as of the
Closing and covering the following matters:
(A) The Company has been duly incorporated and is
validly existing and in good standing under the laws of
the State of Delaware. The Company has all requisite
corporate power and corporate authority to issue the
Shares, to perform its obligations under this Agreement,
to own its properties, and to carry on its business as, to
our knowledge, it is now conducted.
(B) The Agreement has been duly authorized,
executed and delivered on the part of the Company and is a
valid and binding obligation of the Company, enforceable
against the Company in accordance with its terms, subject,
as to enforcement, (i) to bankruptcy, insolvency,
reorganization, arrangement, moratorium, and other laws of
general applicability relating to or affecting creditors'
rights, (ii) to general principles of equity, whether such
enforcement is considered in a proceeding in equity or at
law, and (iii) to limitations imposed by applicable law or
public policy on the enforceability of the indemnification
provisions contained in the Agreement.
(C) The Shares, when issued at the Closing in
compliance with the Agreement, will be duly authorized,
validly issued, fully paid, and non-assessable and free of
preemptive rights set forth in the Articles or Bylaws, or
of which we have knowledge; provided, however, that the
Shares may be subject to restrictions on transfer under
state and federal securities laws.
2
<PAGE> 3
(D) No governmental consents, approvals,
authorizations, registrations, declarations, or filings
are required for the execution and delivery of the
Agreement on behalf of the Company and performance of the
Agreement by the Company, including the issuance of the
Shares, except (i) the qualification (or taking such
action as may be necessary to secure an exemption from
qualification, if available) for the offer and sale of the
Shares under applicable blue sky laws, and (ii) filing of
a registration statement, and an order of the Securities
and Exchange Commission (the "Commission") declaring such
registration statement effective, as contemplated by
Section 8 of the Agreement. To our knowledge, there are no
proceedings pending or threatened that question the
validity of the Agreement.
(E) Subject to the accuracy of the Investor
representations in Section 6 of the Agreement and the
statement in the Officer's Certificate that the Company
has not offered or sold Shares by means of advertising or
public solicitation, the offer, sale, and issuance of the
Shares in conformity with the terms of the Agreement
constitute transactions exempt from the registration
requirements of Section 5 of the Securities Act of 1933,
as amended, and from the qualification requirements of the
California Corporate Securities Law of 1968, as amended.
(F) To our knowledge, there are no actions,
proceedings or governmental investigations pending or
threatened against the Company that question the validity
of the Agreement or the Company's right to enter into the
Agreement, and to our knowledge there is no litigation
pending against the Company or its properties other than
as disclosed in the Company's filings with the Commission.
(v) Such additional supporting documentation and other
information as the Investor or legal counsel for the Investor may
reasonably request.
3. Use of Proceeds. The Company shall use the proceeds from the
transactions contemplated hereby as working capital for general corporate
purposes.
4. Representations and Warranties of the Company. To induce the Investor
to enter into this Agreement and to purchase the Shares, the Company hereby
represents and warrants to the Investor the following, except as disclosed in
the Schedule 4 attached
3
<PAGE> 4
hereto, which exceptions shall be set forth in reasonable detail and reference
the appropriate subsection(s) of this Section 4:
(a) Organization, Standing, Etc. The Company is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Delaware and has the requisite corporate power and authority to own or lease its
properties and to carry on its business as it is now being conducted. The
Company has the requisite corporate power and authority to issue the Shares and
to perform its obligations under this Agreement.
(b) Governing Instruments. The copies of the certificate of
incorporation and bylaws of the Company, and all amendments thereto
(collectively, the "Charter Documents"), as contained or incorporated by
reference in the SEC Filings (as defined in Section 4(r)), are true and complete
copies of the duly and legally adopted Charter Documents in effect as of the
date of this Agreement.
(c) Qualification. The Company has not failed to qualify, be licensed
or domesticated in any jurisdiction in which the failure to so qualify, be
licensed or domesticated would have a material adverse effect upon its business,
properties, operations or financial condition ("Material Adverse Effect").
(d) Financial Statements. The (i) audited financial statements of the
Company for the fiscal years ended December 31, 1996 and 1995, and (ii)
unaudited interim financial statements for the period ended September 30, 1997,
together with the notes thereto, complete and correct copies of which are
included in the SEC Filings (collectively, the "Financial Statements"), present
fairly the financial position of the Company, as of such dates and the results
of operations for the periods covered thereby (subject, in the case of such
unaudited interim financial statements, to year-end audit adjustments) and have
been prepared in accordance with generally accepted accounting principles
consistently applied. Except as set forth in the Financial Statements or
described in the notes thereto, the Company does not have any liabilities,
contingent or otherwise, other than (i) liabilities incurred in the ordinary
course of business subsequent to September 30, 1997; (ii) obligations under real
and personal property leases disclosed in the notes to the Financial Statements
or not required, under generally accepted accounting principles, to be so
disclosed, and (iii) obligations under contracts and commitments incurred in the
ordinary course of business and not required under generally accepted accounting
principles to be reflected in the Financial Statements, which, individually or
in the aggregate, are not material to the financial condition or operating
results of the Company. Except as set forth in Schedule 4, since September 30,
1997, (i) there has been no material adverse change in the business or
condition, financial or otherwise, operations or prospects of the Company, (ii)
to the Company's knowledge, neither the business, condition or operations of the
Company nor any of its properties or
4
<PAGE> 5
assets have been materially adversely affected as the result of any legislative
or regulatory change, any revocation or change in any franchise, permit,
license, or right to do business, or any other event or occurrence, whether or
not insured against, (iii) the Company has not entered into any material
transaction other than in the ordinary course of business, made any distribution
on its capital stock, or redeemed or repurchased any of its capital stock; and
(iv) there has been no lien or encumbrance placed upon any property of the
Company. Notwithstanding and in modification of the immediately preceding
sentence, various risk factors and various facts and uncertainties attendant to
the Company's current operations and financial condition have been disclosed in
the SEC Filings.
(e) Valid Issuance. The Shares, when issued and delivered pursuant to
the terms of this Agreement, will be duly authorized, validly issued and
enforceable in accordance with their respective terms and the terms of this
Agreement.
(f) Corporate Acts and Proceedings. This Agreement has been duly
authorized by all necessary corporate action on behalf the Company, has been
duly executed and delivered by authorized officers of the Company, is a valid
and binding agreement on the part of the Company and is enforceable against the
Company in accordance with its terms. All corporate actions necessary to the
authorization, creation, issuance and delivery of the Shares have been taken by
the Company.
(g) Tax Returns and Audits. The Company has prepared and timely filed
all federal, state and other tax returns required by law to be filed, has paid
or made provision for the payment of all taxes shown to be due and all
additional assessments, and adequate provisions have been made and are reflected
in the Financial Statements to the extent required by generally accepted
accounting principles for all current taxes and other charges to which the
Company is subject and which are not currently due and payable. None of the
income tax returns of the Company have been audited by the Internal Revenue
Service or the state taxing authority in such a manner to bring such audit to
the attention of the Company. The Company does not know of any additional
assessments or adjustments pending or threatened against the Company or its
assets for any period, nor of any basis for any such assessment or adjustment,
which would have a Material Adverse Effect.
(h) Litigation; Government Proceedings. Except as disclosed in the
notes to the Financial Statements and the SEC Filings, there are no legal
actions, suits, arbitrations or other legal, administrative or governmental
proceedings pending or, to the knowledge of the Company, threatened against the
Company, or its properties or business or any executive officer or director of
the Company, and neither the Company nor any executive officer or director of
the Company is aware of any facts which are probable to result in or form the
reasonable basis for any such action, suit or other proceeding. The Company is
not in default with respect to any judgment order or decree of any court or
5
<PAGE> 6
any governmental agency or instrumentality. To the best of its knowledge, the
Company has not been threatened with any action or proceeding under any business
or zoning ordinance, law or regulation.
(i) Compliance with Applicable Laws and Other Instruments. The
properties, business and operations of the Company have been and are being
conducted in all material respects in accordance with all applicable laws, rules
and regulations of all governmental authorities. Neither the execution nor
delivery of, nor the performance of or compliance with this Agreement, the
issuance of the Shares nor the consummation of the transactions contemplated
hereby will, with or without the giving of notice or passage of time, result in
any breach of, or constitute a default under, or result in the imposition of any
lien or encumbrance upon any asset or property of the Company pursuant to, any
agreement or other instrument to which the Company is a party or by which it or
any of its properties, assets or rights is bound or affected, and will not
violate the Charter Documents. The Company is not in violation of its Charter
Documents and, except as disclosed in the SEC Filings, it is not in violation
of, or in default under, any lien, indenture, loan or credit agreement mortgage,
lease, agreement, instrument, commitment or arrangement in any material respect.
(j) Securities Laws. Based in part upon the representations of the
Investor in Section 6, no consents authorization, approval, permit or order of
or filing with any governmental or regulatory authority is required under
current laws and regulations in connection with the execution and delivery of
this Agreement or the offer, issuance, sale or delivery of the Shares, other
than the filing of a Form D pursuant to Regulation D under the Securities Act of
1933, as amended (the "Securities Act"), the filing of a notice on Form 25102(f)
with the State of California and a similar notice with any other state whose
laws require such filing, and the qualification thereof, if required, under
other applicable state laws which qualification has been or will be effected as
a condition of this transaction. Under the circumstances contemplated by this
Agreement, the offer, issuance, sale and delivery of the Shares will not, under
current laws and regulations, require compliance with the prospectus delivery or
registration requirements of the Securities Act.
(k) Patents and Other Intangible Rights. Except as disclosed in the
SEC Filings, the Company (i) owns or has the right to use, free and clear of all
liens, claims and restrictions, all patents, patent applications, trademarks,
service marks, trade names, copyrights, trade secrets, licenses and similar
rights with respect to the foregoing, necessary for and used in the conduct of
its business as now conducted and as proposed to be conducted, to the Company's
knowledge, without infringing upon or otherwise acting adversely to the right or
claimed right of any person under or with respect to any of the foregoing; (ii)
is not contractually or, to the Company's knowledge, otherwise obligated to make
any material payments by way of royalties, fees or otherwise to any owner of,
6
<PAGE> 7
licensor of, or other claimant to, any patent, trademark, service mark, trade
name, copyright, trade secret or other intangible asset, with respect to the use
thereof or in connection with the conduct of its business or otherwise; (iii)
has not received any notice of conflict with the asserted rights of others with
respect to such matters; (iv) to the Company's knowledge, owns or has the
unrestricted right to use all trade secrets, including know-how, customer lists,
inventions, designs, processes, computer programs and technical data used by the
Company in the development, operation and sale of all products and services sold
by it, free and clear of any rights, liens or claims of others; and (v) to the
Company's knowledge, is not using any confidential information or trade secrets
of others.
(l) Capital Stock. The authorized and issued capital stock of the
Company as of the date hereof is correctly set forth in the Financial Statements
for the quarter ended September 30, 1997. All of the outstanding shares of the
Company were duly authorized and validly issued and are fully paid and
nonassessable. Except as described in the SEC Filings, there are no outstanding
subscriptions, options, warrants, calls, contracts, demands, commitments,
convertible securities or other agreements or arrangements of any character or
nature whatever, other than this Agreement, pursuant to which the Company is
obligated to issue any securities of any kind representing an ownership interest
in the Company. Neither the offer nor the issuance or sale of the Shares
constitutes an event under any anti-dilution provisions of any securities issued
(or issuable pursuant to outstanding rights, warrants or options) by the Company
or any agreements with respect to the issuance of securities by the Company,
which will either increase the number of securities issuable pursuant to such
provisions or decrease the consideration per share to be received by the Company
pursuant to such provisions. No holder of any securities of the Company is
entitled to any preemptive or similar rights to purchase any securities of the
Company from the Company.
(m) Assets and Contracts. The Company has included (or incorporated
by reference) in the SEC Filings all material agreements and contracts, has
provided in the SEC Filings a true and complete list of such agreements and
contracts required to be so filed under the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), and has not entered into any such material
agreements since the date of its most recent filing under the Exchange Act.
Except as disclosed in the SEC Filings, the Company has in all material respects
substantially performed its obligations required to be performed by it to date
and is not in default in any material respect under any contracts, agreements,
leases, documents, commitments or other arrangements to which it is a party or
by which it is otherwise bound. Except as disclosed in the SEC Filings, there is
not under any of such agreements, any existing material default or event of
default or event which, with notice or lapse of time or both, would constitute
an event of default by the Company thereunder.
7
<PAGE> 8
(n) Insurance Coverage. The Company has in full force policies of
insurance issued by insurers of recognized responsibility insuring the Company
and its properties and business against such losses and risks, and in such
amounts, as in the Company's judgment, are acceptable for the nature and extent
of such business and its resources. The Company is not in default with respect
to any material provision contained in any insurance policy, and has not failed
to give any notice or present any material existing claims it has under its
insurance policies in a timely fashion.
(o) Employees. To the Company's knowledge, no officer of the Company
or employee of the Company (whose annual compensation is in excess of $80,000)
has any present plans to terminate his or her employment with the Company. Each
officer and other employee of the Company having access to the confidential and
proprietary information of the Company has executed an agreement with the
Company regarding confidentiality and proprietary information.
(p) Retirement Plans. The Company does not have any retirement plan
in which any employee of the Company participates that is subject to any
provisions of the Employee Retirement Income Security Act of 1974 and of the
regulations adopted pursuant thereto.
(q) No Brokers or Finders. Except for the commission payable to
Sunrise Securities Corp. described in Section 6 (1), no person, firm or
corporation has or will have, as a result of any contractual undertaking by the
Company, any right, interest or valid claim against the Company or the Investor
for any commission, fee or other compensation as a finder or broker, or in any
similar capacity, in connection with the transaction contemplated by this
Agreement. The Company will indemnify and hold the Investor harmless against any
and all liability with respect to any such commission fee or other compensation
which may be payable or determined to be payable.
(r) Company SEC Filings. The Company has furnished, or made available
through the EDGAR Internet web site of the Commission, to the Investor true and
complete copies of its Annual Report on Form 10-KSB for the fiscal year ended
December 31, 1996 and its quarterly report on Form 10-QSB for the quarter ended
September 30, 1997, in each case as filed with the Commission (such documents
are collectively referred to herein as the "SEC Filings"). As of their
respective filing dates, the SEC Filings complied in all material respects with
the applicable requirements of the Exchange Act, and none of the SEC Filings
contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements
made therein, in the light of the circumstances under which they were made, not
misleading.
8
<PAGE> 9
(s) Full Disclosure. The Company has not knowingly withheld from the
Investor any material facts relating to the assets, business, operations,
financial condition or prospects of the Company. No representation or warranty
in this Agreement or in any written certificates schedule, statement or other
document prepared by or on behalf of the Company and furnished by the Company to
any Investor pursuant hereto, including without limitation Schedule 4 to this
Agreement, and none of the SEC Filings, as of the date furnished to the Investor
or filed under the Exchange Act, as the case may be, contained any untrue
statement of a material fact or omitted to state any material fact required to
be stated herein or therein necessary to make the statements herein or therein
not misleading.
5. Transfer Restrictions.
(a) The Investor realizes that the Shares are not registered under
the Securities Act, or any foreign or state securities laws. The Investor agrees
that the Shares will not be sold, offered for sale, pledged, hypothecated, or
otherwise transferred (collectively, "Transfer") except in compliance with the
Act, if applicable, and applicable foreign and some securities laws. Purchasers
of Shares can only Transfer the Shares pursuant to registration under the Act or
pursuant to an exemption therefrom. The Investor understands that to Transfer
the Shares may require in some jurisdictions specific approval by the
appropriate governmental agency or commission in such jurisdiction. The Investor
has been advised that, except as set forth in Section 5, the Company has no
obligation, and does not intend, to cause the Shares to be registered under the
Act or the securities law of any other jurisdiction or to comply with the
requirements for any exemption under the Act, including but not limited to those
provided by Rule 144 and Rule 144A promulgated under the Act, or under the
securities law of any other jurisdiction.
(b) To enable the Company to enforce the transfer restrictions
contained in Section 3(a), the Investor hereby consents to the placing of
legends upon, and stop-transfer orders with the transfer agent of the Common
Stock with respect to, the Shares.
6. Representations, Warranties and Covenants. To induce the Company to
accept the Investor's subscription, the Investor hereby represents, warrants and
covenants to the Company that:
(a) the Investor is duly authorized to execute this Subscription
Agreement and this Subscription Agreement, when executed and delivered by the
Investor, will constitute a legal, valid, and binding obligation enforceable
against the Investor in accordance with its terms; and the execution, delivery,
and performance of this Subscription Agreement and the consummation of the
transactions contemplated
9
<PAGE> 10
hereby have been duly authorized by all requisite corporate or other necessary
action on the part of the Investor;
(b) the Shares subscribed for hereby are being acquired by the
Investor for investment purposes only, for the account of the Investor and not
with the view to any resale or distribution thereof, and the Investor is not
participating, directly or indirectly, in a distribution of such Shares and will
not take, or cause to be taken, any action that would cause the Investor to be
deemed an "underwriter" of such Shares as defined in Section 2(11) of the Act;
(c) the Investor has had access to all materials, books, records,
documents, and information relating to the Company, including (i) the
Registration Statement on Form S-3 filed January 17, 1997 (the "Registration
Statement"), (ii) the Annual Report on Form 10-KSB for the year ended December
31, 1996, (iii) the Quarterly Report on Form 10-QSB for the quarter ended
September 30, 1997 (the "Form 10-QSB") and (iv) the Proxy Statement dated May 9,
1997, and has been able to verify the accuracy of the information contained
therein;
(d) the Investor acknowledges and understands that investment in the
Shares involves a high degree of risk, including without limitation the risks
set forth in the Registration Statement under the caption "Risk Factors" and in
the Form 10-QSB under the caption "Factors Affecting Future Results" in
"Management's Discussion and Analysis of Financial Condition and Results of
Operations;"
(e) the Investor acknowledges that the Investor has been offered an
opportunity to ask questions of, and receive answers from, officers of the
Company concerning all material aspects of the Company and its business, and
that any request for such information has been fully complied with to the extent
the Company possesses such information or can acquire it without unreasonable
effort or expense;
(f) the Investor has such knowledge and experience in financial and
business matters that the Investor is capable of evaluating the merits and risks
of an investment in the Company and can afford a complete loss of his investment
in the Company;
(g) the Investor has never been notified by the Internal Revenue
Service that the Investor is subject to backup withholding;
(h) the Investor recognizes that no governmental agency has passed
upon the issuance of the Shares or made any finding or determination as to the
fairness of this investment;
10
<PAGE> 11
(i) if the Investor is purchasing the Shares subscribed for hereby in
a representative or fiduciary capacity, the representations and warranties
contained herein shall be deemed to have been made on behalf of the person or
persons for whom such Shares are being purchased;
(j) the Investor has not entered into any agreement to pay
commissions to any persons with respect to the purchase or sale of the Shares,
except commissions for which the Investor will be responsible;
(k) the Investor acknowledges that the Company will pay to Sunrise
Securities Corp. a commission with respect to the sale of the Shares by the
Company to the Investor of (i) 6.5% payable at the option of the Sunrise
Securities Corp. in cash or shares of Common Stock valued at $2.00 per share and
(ii) five-year warrants to purchase, at a purchase price of $2.00 per share,
that number of shares of Common Stock equal to 10% of the number of Shares being
purchased by the Investor hereunder and will reimburse Sunrise Securities Corp.
for all documented out-of-pocket expenses incurred in connection with this
transaction up to a maximum of 2% of the Purchase Price;
(l) the Investor is an "Accredited Investor" as that term is defined
in Section 501(a) of Regulation D promulgated under the Act; and
(m) as soon as practicable after the Closing, the Investor shall
designate a nominee to be appointed to the Board of Directors pursuant to
Section 7(b).
7. Covenants of the Company. The Company covenants and agrees as
follows:
(a) Delivery of Information. The Company will deliver to the Investor
promptly upon transmission thereof, copies of all publicly available reports,
proxy statements, registration statements and notifications filed by the Company
with the Commission or furnished to stockholders of the Company or to any
securities exchange, including. without limitation, filings on Form 10-QSB, Form
10-KSB and Form 8-K, and any amendments thereto.
(b) Representation of Directors. The Company shall take all action
reasonably necessary to appoint the Investor's nominee pursuant to Section 6(m)
to the Board of Directors; provided, however, that the Investor shall have no
right to designate a member of the Board of Directors pursuant to this Agreement
at such time as the Investor and its affiliates fails to own at least 2,600,000
shares of Common Stock.
(c) Anti-dilution. In the event the Company sells any shares of its
Common Stock (or securities convertible into Common Stock) to any third party
for a period of six months after the date of this Agreement (other than pursuant
to the exercise
11
<PAGE> 12
or conversion of securities outstanding as of the date hereof or to existing
employee stock option plans) at a price per share (the "New Per Share Price")
lower than $1.75; then the Company shall issue to the Investor an additional
number of shares of Common Stock so that the per Share price paid by the
Investor equals the New Per Share Price (the "Adjusted Purchase Price"). Upon
subsequent issuances by the Company during the six-month period, this Section
shall continue to apply to issuances at a price per share lower than the
Adjusted Purchase Price then in effect.
(d) Issuance of Additional Shares. Without the prior written consent
of the Investor, which consent shall not be unreasonably withheld or delayed
(provided that it shall not be considered unreasonable to withhold consent to a
sale of securities at a purchase price of less than $1.75 per share), for a
period of six months from the date hereof, the Company shall not issue
additional equity securities (or securities convertible into equity securities)
at a purchase price of less than $2.25 per share other than (i) to employees or
consultants under the Company's existing stock option plans, (ii) shares of
Common Stock issued in connection with the offering of which the Shares are a
part, provided that such offering must be completed no later than December 31,
1997 on terms no more favorable than those received by Investor hereunder and at
a purchase price of not less than $1.75 per share, and the Company may issue a
total of no more than $10 million of such shares, and (iii) in connection with
strategic alliances, joint ventures or other corporate partnerships.
(e) Right of First Refusal. For a period of twelve months following
the date hereof, in the event, and each time, that the Company issues any
additional shares of its capital stock, other than through a public offering,
the Investor shall have a right of first refusal, for a period of 30 days after
written notice from the Company, to purchase all or any portion of such
additional shares of capital stock as specified below. The purchase price for
such additional shares of capital stock under this right of first refusal shall
be the price offered to or proposed to be paid by the intended purchasers.
Failure to respond in writing to the Company's written notice within the 30-day
period shall be deemed to be an election not to participate. In the event there
are any shares for which the right of first refusal is not exercised pursuant to
this Section, the Company may issue such shares to the intended purchasers on
the same terms offered to the Investor, provided that such sale must be
completed with 60 days following the date on which the period for the Investor
to elect to participate has been waived or expired. For purposes of this
section, the issuance by the Company of any warrant or right to purchase or
subscribe to another security, or the issuance of a security which gives the
holder a present or future right or privilege to convert the security into
another security, shall be deemed to include the issuance of the underlying
security at the time of the issuance of the warrant or right or convertible
security, but the subsequent exercise of the right to purchase or subscribe or
to convert shall not be deemed an issuance subject to this right of first
refusal. The right of first refusal shall not apply to any additional shares of
capital stock (i) issued to
12
<PAGE> 13
employees or directors of (or consultants to) the Company, or issuable upon
exercise of stock options granted so such employees, directors or consultants,
pursuant to stock-based compensation plans approved by the Board, (ii) issued or
issuable by way of stock split or stock dividend or similar capital
modification, (iii) issued in connection with the sale of the Common Stock in a
public offering registered under the Securities Act, (iv) issued in connection
with a bona fide business acquisition of or by the Company (whether by merger,
consolidation, or the sale or exchange of assets or stock or otherwise), (v)
issuable upon exercise or conversion of any exchangeable or convertible
securities outstanding as of the date hereof, or (vi) issued in connection with
strategic alliances, joint ventures or other corporate partnerships.
8. Registration of Shares under the Act.
(a) The Company shall, at its expense, (i) not later than the earlier
of (x) January 30, 1998 or (y) 30 business days after the final closing of the
offering of which the Shares are a part (in either case, the "Filing Deadline")
file a registration statement (the "Registration Statement") with the Commission
to register under the Act the resale by the Investor of the Shares, (ii) use its
reasonable best efforts to cause the Registration Statement to become effective
under the Act as promptly as practicable, (iii) after the Registration Statement
is declared effective under the Act, furnish the Investor with such number of
copies of the prospectus (the "Prospectus") included in the Registration
Statement as the Investor may reasonably request to facilitate the resale of the
Shares; and (iv) use its reasonable best efforts to cause such Registration
Statement to remain effective until such time as the Investor becomes eligible
to resell the Shares pursuant to Rule 144.
(b) The Investor shall give at least three business days' prior
written notice (a "Sale Notice") to the Company of any proposed sale of Shares
under the Registration Statement (provided, however, that such notice shall not
be required during the 45-day period immediately following the date on which the
Registration Statement first becomes effective) and shall not make such sale (i)
unless such three days lapse without response from the Company, or (ii) in the
event the Company responds by stating that a Prospectus supplement or
post-effective amendment will be filed pursuant to Section 5(c), until the
Company has notified the Investor pursuant to Section 5(c) that any such
post-effective amendment has become effective or Prospectus supplement has been
filed. A Sale Notice shall be effective for 45 days after it is given.
(c) The Company will prepare and file with the Commission such
amendments and Prospectus supplements, including post-effective amendments, to
the Registration Statement as the Company determines may be necessary or
appropriate, and use its reasonable best efforts to have such post-effective
amendments declared effective as promptly as practicable; cause the Prospectus
to be supplemented by any Prospectus
13
<PAGE> 14
supplement, and as so supplemented, to be filed with the Commission; and notify
the Investor when a Prospectus, and any Prospectus supplement or post-effective
amendment must be filed or has been filed (including any filing in response to a
Sale Notice) and, with respect to any post-effective amendment, when the same
has become effective.
(d) Notwithstanding any other provision hereof, commencing 45 days
after the Registration Statement has been declared effective the Company may
delay the Investor's ability to resell Shares pursuant to the Registration
Statement if the Company delivers a certificate in writing to the Investor,
which writing states the basis therefore, to the effect that a delay in such
sale is necessary because, in the good faith and reasonable judgment of the
Company's Board of Directors, (i) a sale pursuant to the Registration Statement
would require the public disclosure of information that would materially
adversely affect the strategic interests of the Company; (ii) is likely to
materially adversely affect the Company, provided, the Company shall not delay
more than one such sale for such reason; or (iii) could constitute a violation
of the federal securities laws. In such an event, the Company shall notify the
Investor promptly after it is determined that such circumstances no longer
exist.
(e) In connection with the Registration Statement, the Investor shall
furnish to the Company such information as the Company shall reasonably request.
(f) In the event that the Company shall fail to file a timely
Registration Statement in accordance with Section 8(a)(i) above, the Company
shall issue to the Investor, as compensation therefor, shares of Common Stock
equal to (i) 1% of the Shares for each 30 days or part thereof the filing is
delayed until 60 days after the Filing Deadline and (ii) 2% of the Shares for
each 30 days or part thereof the filing is delayed from 60 days and after the
Filing Deadline; provided, however, that the Company shall not be required to
issue such shares if such failure has been caused by the failure of the Investor
to provide information in connection with the Registration Statement in
accordance with Section 8(e) above.
9. Indemnification.
(a) The Investor understands the meaning and legal consequences of
the representations and warranties made by the Investor in this Agreement, and
agrees to indemnify and hold harmless the Company and each of the Company's
directors, officers, stockholders, employees, counsel, agents, successors, and
assigns, if any, from and against any and all loss, damage, liability, or
expense (including, without limitation, attorneys' fees), as and when incurred,
due to or arising out of (in each case in whole or in part) any breach of any
representation or warranty made by the Investor set forth herein or in any other
agreement or other document furnished by the Investor to any of the foregoing in
connection with this transaction, any failure by the Investor to fulfill any of
14
<PAGE> 15
its covenants or agreements set forth herein or therein, or arising out of the
resale or distribution by the Investor of the Shares or any portion thereof in
violation of the Act or any applicable foreign or state securities or "blue sky"
law.
(b) The Company understands the meaning and legal consequences of the
representations and warranties made by it in this Agreement, and agrees to
indemnify and hold harmless the Investor and each of the Investor's directors,
officers, stockholders, employees, counsel, agents, successors, and assigns, if
any, from and against any and all loss, damage, liability, or expense
(including, without limitation, attorneys' fees), as and when incurred, due to
or arising out of (in each case in whole or in part) any breach of any
representation or warranty made by the Company set forth herein, any failure by
the Company to fulfill any of its covenants or agreements set forth herein.
10. Further Documents. The Investor agrees that it will execute such
other documents as may be necessary or desirable in connection with the
transactions contemplated hereby.
11. Payment of Fees and Expenses of the Investor. The Company agrees to
reimburse the Investors for their out-of-pocket expenses, including reasonable
legal expenses incurred for one special legal counsel to the Investor,
Oppenheimer, Wolff & Donnelly, in connection with the transactions contemplated
by this Agreement, up to a maximum aggregate of $15,000.
12. Modification. Neither this Subscription Agreement nor any provisions
hereof shall be waived, modified, discharged, or terminated except by an
instrument in writing signed by the party against whom any such waiver,
modification, discharge, or termination is sought.
13. Notices. Any notice or other communication required or permitted to
be given hereunder shall be in writing and shall be mailed by certified mail,
return receipt requested, or by Federal Express, Express Mail or similar
overnight delivery or courier service and delivered (in person or by telecopy,
telex or similar telecommunications equipment) against receipt to the party to
whom it is to be given, (i) if to the Company, at its address set forth on the
first page hereof, (ii) if to the Investor, at its address set forth on the
signature page hereto, or (iii) in either case, to such other address as the
party shall have furnished in writing in accordance with the provisions of this
Section 9. Notice to the estate of any party shall be sufficient if addressed to
the party as provided in this Section 9. Any notice or other communication given
by certified mail shall be deemed given at the time of certification thereof,
except for a notice changing a party's address which shall be deemed given at
the time of receipt thereof. Any notice given by other means permitted by this
Section 9 shall be deemed given at the time of receipt thereof.
15
<PAGE> 16
14. Counterparts. This Subscription Agreement may be executed through
the use of separate signature pages or in any number of counterparts, and each
such counterpart shall, for all purposes, constitute one agreement binding on
all parties, notwithstanding that all parties are not signatories to the same
counterpart.
15. Entire Agreement. This Subscription Agreement contains the entire
agreement of the parties with respect to the subject matter hereof and there are
not representations, covenants or other agreements except as stated or referred
to herein.
16. Severability. Each provision of this Subscription Agreement is
intended to be severable from every other provision, and the invalidity or
illegality of any portion hereof shall not affect the validity or legality of
the remainder hereof.
17. Assignability. This Subscription Agreement is not transferable or
assignable by the Investor.
18. Applicable Law. This Subscription Agreement has been negotiated and
consummated in the State of California and shall be governed by and construed in
accordance with the laws of the State of California, without giving effect to
conflict of laws.
19. Choice of Jurisdiction. Any action or proceeding arising, directly,
indirectly, or otherwise, in connection with, out of or from this Subscription
Agreement, any breach hereof or any transaction covered hereby shall be resolved
within San Francisco, California. Accordingly, the parties consent and submit to
the jurisdiction of the United States federal and state courts located within
San Francisco, California.
20. Taxpayer Identification Number. The Investor verifies under
penalties of perjury that any Taxpayer Identification Number or Social Security
Number shown on the signature page hereto is true, correct, and complete.
21. Pronouns. Any personal pronoun shall be considered to mean the
corresponding masculine, feminine, or neuter personal pronoun, as the context
requires.
16
<PAGE> 17
IN WITNESS WHEREOF, the Investor has executed this Subscription
Agreement this 12th day of December, 1997.
GRACE BROTHERS, LTD.
By: /s/ Bradford T. Whitmore
-------------------------------------
Name: Bradford T. Whitmore
Title: General Partner
-----------------------------------------
1560 Sherman Avenue, Suite 900
(Address)
Evanston, IL 60201
-----------------------------------------
(City, State and Zip Code)
(847) 733-1230
-----------------------------------------
(Telephone Number)
(847) 733-0342
-----------------------------------------
(Telecopier Number)
36-3417056
-----------------------------------------
(Tax I.D. or Social Security Number)
ACCEPTED AND AGREED:
LXR BIOTECHNOLOGY, INC.
By: /s/ L. David Tomei
-------------------------------
Name: L. David Tomei
-----------------------------
Title: Chief Executive Officer
----------------------------
Date: December 12, 1997
17
<PAGE> 1
Exhibit 99.1
LXR BIOTECHNOLOGY INC. CLOSES PRIVATE PLACEMENT
Richmond, Calif. -- December 15, 1997 -- LXR Biotechnology Inc. (AMEX:LXR)
announced today that it has sold 3,428,572 shares of its common stock in a
private placement at $1.75 per share resulting in gross proceeds of
approximately $6 million. The net proceeds, expected to be approximately $5.5
million, are to be used for research and development and general working
capital.
The securities offered in the private placement have not been registered under
the Securities Act of 1933 and may not be offered or sold in the United States
absent registration or an applicable exemption from registration requirements.
The Company has agreed to file a registration statement to cover resales by the
purchaser.
LXR Biotechnology Inc., based in Richmond, Calif., is a biopharmaceutical
company engaged in the research and development of innovative therapeutics
designed to treat diseases through the control of apoptosis or programmed cell
death. The Company, which employs approximately 66 people, was founded in 1992,
and completed its initial public offering in May 1994. Further information on
LXR may be obtained from the Company's SEC filings or by contacting the Company
directly.
Statements in this press release that are not historical are forward looking
statements. These forward looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially from those
anticipated in any forward looking statements, all of which are difficult to
predict and many of which are beyond the control of the Company, including, but
not limited to the risks and uncertainties detailed in the company's periodic
reports and registration statements filed with the Securities and Exchange
Commission. LXR does not undertake to revise or update any forward looking
statements to reflect events or circumstances that may arise after the date
hereof.
